Would the Physicians Eventually Obsolete the Liver Biopsy for the Assessment of Liver Fibrosis?

Hadi Parsian 1,2*, Maryam Alizadeh 2, Hajar Negahdar 2

1 Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, IR Iran
2 Departments of Biochemistry and Biophysics, Babol University of Medical Sciences, Babol, IR Iran

Dear Editor,

In recent article which is published in your journal Crisan D et al. (1) has been reported an interesting article about noninvasive assessment of liver fibrosis. They evaluated six serum marker panels (APRI, Forns, Fib-4, Hepascore, Fibro Test, Fibro meter) and transient elastography (TE) alone or in combination, for prediction of liver fibrosis stages in 446 chronic hepatitis C (CHC) patients. In addition they evaluated whether the combination of serum panels with TE could increase the diagnostic accuracy of liver fibrosis assessment or not. The authors concluded that combination of some of previously mentioned serum marker panels with TE increases the diagnostic accuracy of non-invasive methods for the assessment of liver fibrosis stage. Studies such as previously mentioned article are very important, because the findings would help us to improve our knowledge about the staging of liver fibrosis. Nowadays the list of serum marker algorithms for assessment of liver fibrosis stages in all liver fibrosis diseases is increasing. According to the literature, there are various

* Corresponding author: Hadi Parsian, Babol University of Medical Sciences, Ganjafrooz Ave, Babol, IR Iran. Tel: +98-1112190569, Fax: +98-1112190569, E-mail: hadiparsian@yahoo.com
DOI:10.5812/hepatmon.6227
Copyright © 2012 Kowsar Corp. All rights reserved.
any etiology) with a simple and noninvasive method. To reach to this issue many studies have been done and various noninvasive serum marker panels were compared. Most of these studies compared the diagnostic accuracy of noninvasive markers with liver fibrosis and our knowledge about liver necro-inflammatory injuries is relatively low. As a try to evaluate the diagnostic accuracy of some of these biomarkers in liver fibrosis with the etiology other than viral hepatitis C, we examined the efficacy of some of these serum marker panels in chronic hepatitis C, B and autoimmune hepatitis patients’ simultaneously. The results showed that in spite of the differences in the etiology of liver fibrosis, measurement of serum laminin (LN), N terminal peptide of procollagen type III (PIIINP), AAR (AST to ALT), AP (Age-platelet index), APRI, FIB-4 and FibroQ score (derived from this simple formula: Fibro Q = \left(\frac{\text{AST} \times \text{INR}}{\text{PLT} \times \text{ALT}}\right)\times 10 \times \text{age in years}) concentrations can discriminate between patients with liver fibrosis and healthy individuals and it seems only the extracellular matrix components i.e. LN and PIIINP performed better at excluding advanced fibrosis than mild fibrosis. (10). In conclusion we think that it is need for some big studies to examined the efficacy of these serum marker panels, alone or in combination, with newer noninvasive tests (but more expensive such as TE), in various etiology of liver disease. Perhaps with finding upright results in various etiologies of liver diseases, eventually we can obsolete liver biopsy as the gold standard for assessment of liver biopsy.

Acknowledgements
We thank from the patients that permitted us to collect them blood for research.

Authors’ Contribution
H.P: idea, literature reviewing and manuscript writing; MA and H.N: literature reviewing and contribution to manuscript writing.

Financial Disclosure
None Declared.

Funding Support
None Declared.

References